Last reviewed · How we verify
IR CD-LD
IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control.
IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control. Used for Parkinson's disease motor symptoms.
At a glance
| Generic name | IR CD-LD |
|---|---|
| Also known as | immediate-release carbidopa-levodopa, Generic for Sinemet tablets |
| Sponsor | Impax Laboratories, LLC |
| Drug class | Dopamine replacement therapy / Decarboxylase inhibitor combination |
| Target | Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain to replace depleted neurotransmitter levels in Parkinson's disease. Carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine outside the central nervous system, allowing more levodopa to reach the brain. The immediate-release formulation aims to provide rapid symptom relief compared to extended-release alternatives.
Approved indications
- Parkinson's disease motor symptoms
Common side effects
- Dyskinesia
- Motor fluctuations
- Nausea
- Orthostatic hypotension
- Hallucinations
Key clinical trials
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease (PHASE2)
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations (PHASE3)
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease (PHASE2)
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa (PHASE2)
- Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IR CD-LD CI brief — competitive landscape report
- IR CD-LD updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI